Intrastriatal transplantation of microcarrier-bound human retinal pigment epithelial cells versus sham surgery in patients with advanced Parkinson's disease: A double-blind, randomised, controlled trial

The Lancet Neurology

Volumn 10, Issue 6, 2011, Pages 509-519

  Gross, Robert E ^a   Watts, Raymond L ^b   Hauser, Robert A ^c   Bakay, Roy AE ^d   Reichmann, Heinz ^e   von Kummer, Rüdiger ^e   Ondo, William G ^f   Reissig, Elke ^g   Eisner, Wilhelm ^h   Steiner Schulze, Heike ^g   Siedentop, Harald ^g   Fichte, Klaus ^g   Hong, Walter ⁱ   Cornfeldt, Michael ^j   Beebe, Katherine ^k   Sandbrink, Rupert ^b,g  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b The University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d RUSH UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

^g BAYER PHARMA AG   (Germany)

^h UNIVERSITY OF INNSBRUCK   (Austria)

ⁱ BAYER CORPORATION   (United States)

^j Titan Pharmaceuticals   (United States)

^k HEINRICH HEINE UNIVERSITY   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

LEVODOPA;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; CELL TRANSPLANTATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HUMAN CELL; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MICROCARRIER CULTURE; NEUROLOGIC DISEASE; PARKINSON DISEASE; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PUTAMEN; RANDOMIZED CONTROLLED TRIAL; RETINA PIGMENT EPITHELIAL CELL; RISK ASSESSMENT; SHAM PROCEDURE; STEREOTAXIC SURGERY; UNIFIED PARKINSON DISEASE RATING SCALE;

ADULT; AGED; CORPUS STRIATUM; DOUBLE-BLIND METHOD; DRUG CARRIERS; EPITHELIAL CELLS; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; PLACEBOS; RETINAL PIGMENT EPITHELIUM; TREATMENT OUTCOME;

EID: 79956077225     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(11)70097-7     Document Type: Article

References (42)

1. Follett KA The surgical treatment of Parkinson's disease. Annu Rev Med 2000, 51:135-147.
2. Rajput AH Clinical features and natural history of Parkinson's disease (special consideration of aging). Neurodegenerative diseases 1994, 555-572. WB Saunders, Philadelphia, PA. D.B. Calne (Ed.).
3. Jankovic J An update on the treatment of Parkinson's disease. Mt Sinai J Med 2006, 73:682-689.
4. Hely MA, Morris JG, Reid WG, Trafficante R Sydney multicenter study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 2005, 20:190-199.
5. Olanow CW, Obeso JA, Stocchi F Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol 2006, 5:677-687.
6. Lindvall O, Björklund A Cell therapy in Parkinson's disease. NeuroRx 2004, 1:382-393.
7. Subramanian T Cell transplantation for the treatment of Parkinson's disease. Semin Neurol 2001, 21:103-115.
8. Freed CR, Greene PE, Breeze RE, et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 2001, 344:710-719.
9. Olanow CW, Goetz CG, Kordower JH, et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 2003, 54:403-414.
10. Schraermeyer U, Kopitz J, Peters S, et al. Tyrosinase biosynthesis in adult mammalian retinal pigment epithelial cells. Exp Eye Res 2006, 83:315-321.
11. Boulton M Melanin and the retinal pigment epithelium. Structure, function, and disease of the retinal pigment epithelium 1998, 68-85. Oxford University Press, New York, NY, USA. M.F. Marmor, T.J. Wolfensberger (Eds.).
12. Kubrusly RC, Guimaraes MZ, Vieira AP, et al. L-DOPA supply to the neuro retina activates dopaminergic communication at the early stages of embryonic development. J Neurochem 2003, 86:45-54.
13. Doudet DJ, Cornfeldt ML, Honey CR, Schweikert AW, Allen RC PET imaging of implanted human retinal pigment epithelial cells in the MPTP-induced primate model of Parkinson's disease. Exp Neurol 2004, 189:361-368.
14. Subramanian T, Marchionini D, Potter EM, Cornfeldt ML Striatal xenotransplantation of human retinal pigment epithelial cells attached to microcarriers in hemiparkinsonian rats ameliorates behavioral deficits without provoking a host immune response. Cell Transplant 2002, 11:207-214.
15. Watts RL, Raiser CD, Stover NP, et al. Stereotaxic intrastriatal implantation of human retinal pigment epithelial (hRPE) cells attached to gelatin microcarriers: a potential new cell therapy for Parkinson's disease. J Neural Transm Suppl 2003, 65:215-227.
16. Stover NP, Bakay RA, Subramanian T, et al. Intrastriatal implantation of human retinal pigment epithelial cells attached to microcarriers in advanced Parkinson disease. Arch Neurol 2005, 62:1833-1837.
17. Bakay RA, Raiser CD, Stover NP, et al. Implantation of Spheramine in advanced Parkinson's disease (PD). Front Biosci 2004, 9:592-602.
18. Stover NP, Watts RL Spheramine for treatment of Parkinson's disease. Neurotherapeutics 2008, 5:252-259.
19. Hagell P, Cenci MA Dyskinesias and dopamine cell replacement in Parkinson's disease: a clinical perspective. Brain Res Bull 2005, 68:4-15.
20. Watts RL, Freeman TB, Hauser RA, et al. A double-blind, randomized, controlled, multicenter clinical trial of the safety and efficacy of stereotaxic intrastriatal implantation of fetal porcine ventral mesencephalic tissue (Neurocell -PD) vs imitation surgery in patients with Parkinson disease (PD). Parkinsonism Relat Disord 2001, 7(suppl):S87.
21. Lang AE, Gill S, Patel NK, et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol 2006, 59:459-466.
22. Marks WJ, Bartus RT, Siffert J, et al. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol 2010, 9:1164-1172.
23. LeWitt PA, Rezai AR, Leehey MA, et al. AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol 2011, 10:309-319.
24. Freed CR, Breeze RE, Rosenberg NL, et al. Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson's disease. N Engl J Med 1992, 327:1549-1555.
25. Hauser RA, Freeman TB, Snow BJ, et al. Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease. Arch Neurol 1999, 56:179-187.
26. Schumacher JM, Ellias SA, Palmer EP, et al. Transplantation of embryonic porcine mesencephalic tissue in patients with PD. Neurology 2000, 54:1042-1050.
27. Gill SS, Patel NK, Hotton GR, et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 2003, 9:589-595.
28. Marks WJ, Ostrem JL, Verhagen L, et al. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol 2008, 7:400-408.
29. Kaplitt MG, Feigin A, Tang C, et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 2007, 369:2097-2105.
30. Farag ES, Vinters HV, Bronstein J Pathologic findings in retinal pigment epithelial cell implantation for Parkinson disease. Neurology 2009, 73:1095-1102.
31. Mendez I, Sanchez-Pernaute R, Cooper O, et al. Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson's disease. Brain 2005, 128:1498-1510.
32. Kordower JH, Rosenstein JM, Collier TJ, et al. Functional fetal nigral grafts in a patient with Parkinson's disease: chemoanatomic, ultrastructural, and metabolic studies. J Comp Neurol 1996, 370:203-230.
33. Cherksey BD, Sapirstein VS, Geraci AL Adrenal chromaffin cells on microcarriers exhibit enhanced long-term functional effects when implanted into the mammalian brain. Neuroscience 1996, 75:657-664.
34. Julien S, Kociok N, Kreppel F, et al. Tyrosinase biosynthesis and trafficking in adult human retinal pigment epithelial cells. Graefes Arch Clin Exp Ophthalmol 2007, 245:1495-1505.
35. Goetz CG, Wuu J, McDermott MP, et al. Placebo response in Parkinson's disease: Comparisons among 11 trials covering medical and surgical interventions. Mov Disord 2008, 23:690-699.
36. Maetzler W, Liepelt I, Berg D Progression of Parkinson's disease in the clinical phase: potential markers. Lancet Neurol 2009, 8:1158-1171.
37. Alves G, Wentzel-Larsen T, Aarsland D, Larsen JP Progression of motor impairment and disability in Parkinson disease: a population-based study. Neurology 2005, 65:1436-1441.
38. Jankovic J, Kapadia AS Functional decline in Parkinson disease. Arch Neurol 2001, 58:1611-1615.
39. Louis ED, Tang MX, Cote L, Alfaro B, Mejia H, Marder K Progression of parkinsonian signs in Parkinson disease. Arch Neurol 1999, 56:334-337.
40. Diederich NJ, Goetz CG The placebo treatments in neurosciences: new insights from clinical and neuroimaging studies. Neurology 2008, 71:677-684.
41. McRae C, Cherin E, Yamazaki TG, et al. Effects of perceived treatment on quality of life and medical outcomes in a double-blind placebo surgery trial. Arch Gen Psychiatry 2004, 61:412-420.
42. Hick J, Feldman SR Eligibility creep: a cause for placebo group improvement in controlled trials of psoriasis treatments. J Am Acad Dermatol 2007, 57:972-976.